This enzyme-radioimmunoassay for the measurement of L-dopa, dopamine, and 3-O-methyldopamine is based on the incubation of urine in the presence of catechol-Omethyltransferase, aromatic-i-amino-acid decarboxylase,
normal subjects (L-dopa 1.3 ± 0.3, dopamine 147 ± 38, and 3-O-methyldopamine 31.4 ± 13.6 g/24 h), hospitalized patients without melanoma, and amelanotic melanoma patients.
However, the excretion rates for these metabolites in melanotic melanoma (L-dopa 5.6 ± 1.2, dopamine 555 ± 121, and 3-O-methyldopamine 178 ± 40.3 g/24 h) were significantly (p <0.005) higher than in control or amelanotic melanoma subjects. After surgery, there was a substantial decrease in urinary output of L-dopa and its metabolites by these patients.
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Melanoma is one of a group of neoplasms, derived histogenetically from the neural crest (1, 2) , that includes the retinoblastomas, neuroblastomas, pheochromocytomas, and ganglioneuromas.
All of these tumors share an ectodermal cellular origin and are characterized biochemically by abnormal tyrosine metabolism.
In normal melanocytes, L-tyrosine is converted to 3,4-dihydroxyphenylalanine (L-dopa), which is then oxidized to dopa quinone by tyrosinase (EC 1.10.3.1), an enzyme present in the melanin granules. Dopa quinone cyclizes spontaneously to form 2-carboxyindole-5,6-quinone, which on decarboxylation yields indole-5,6-quinone For more than 10 years, increased urinary production of melanin precursors and metabolites (indole, catechol, and phenol melanogens) has been recognized as a specific metabolic disorder in melanoma (5, 6) .
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Received . We also examined the effect of local excision on the urinary output of these metabolic intermediates in melanoma patients. 
Materials and Methods

Apparatus
Collection of Specimens, and Patient Population
For measurement of L-dopa, dopamine, and 3-0-methyl- 
Procedures
Isolation of L-dopa from urine. L -Dopa was isolated from urine by ion-exchange chromatography according to a modified procedure of Fahn et al. (10). The cation-exchange resin was purified batchwise by washing successively with 2 mol/L HCI, H20, 2 mol/L NaOH, H2O, 2 mol/L HCI, and H2O. Chromatography columns (180 X 5 mm) were used; each column contained 1 mL (wet bed) of cation-exchange resin.
The pH of the urine sample (20 mL) was adjusted to 2 before it was applied to the column. The column was then washed with 10 mL of water, and the L-dopa in the urine was eluted with 10 mL of sodium phosphate buffer (0.1 mol/L sodium phosphate containing 0.1 mol of NaCl per liter, pH 6.5). LDopa in the eluate from the column was diluted fivefold with water and then analyzed by enzyme-radioimmunoassay as described below.
Enzyme preparation.
An enzymic preparation containing catechol methyltransferase (EC 2.1.1.6; COMT) enriched with decarboxylase activity was formulated according to the following procedure.
Ten Wistar rats were killed by suffocation in a chamber containing solid CO2. Livers (89 g) and kidneys (20 g) were immediately excised and chilled (0 #{176}C). The combined tissues were homogenized with isotonic KCI (400 mL) and centrifuged at 70 000 X g for 40 mm. The supernate was decanted, titrated to pH 5 with 1 mol/L acetic acid, allowed to stand for 10 mm, then centrifuged at 500 X g for 15 mm. The precipitate was discarded and an equal volume of 500 g/L ammonium sulfate solution was added. After centrifugation (500 X g) and dialysis for 6 h vs potassium phosphate buffer (10 mmol/L, pH 7.0, and containing 0.1 mmol of dithiothreitol per liter), 50 mg of dithiothreitol was added to 50 mL of the dialyzed enzyme solution and the mixture was then divided into 1-mL fractions and stored at -80 #{176}C in plastic tubes. The final protein concentration of the enzyme solution was 27 to 35 g/L. The enzyme preparation was stable for at least six months. In each case, the mixture was vortex-mixed and 50 tL of COMT-decarboxylase preparation was added.To determine the presence of 3-O-methyldopamine in the sample alone, we prepared tubes in which 0.25 mL of distilled water was substituted for S-adenosyl-L-methionine (SAM) and COMT. The reaction mixture was incubated for 45 mm at 37 #{176}C in a shaking water bath and the reaction was then stopped by adding borate buffer (4 mL, 0.5 mol/L sodium borate, adjusted to pH 10.5 with a 10 mol/L solution of NaOH). We then added 1.5 g of NaCI and 0.3 g of anhydrous Na2CO:,. The 3-O-methyldopamine generated in the reaction tubes was then extracted into 30 mL of ethyl acetate by shaking the samples with theorganic solvent for 30 mm, then centrifuging (500 X g) for 10 mm. An 25-mL aliquot of the ethyl acetate was removed. To the remaining two-phase mixture, 10 mL of ethyl acetate was added and, after shaking and centrifuging as above, 10 mL of solvent was withdrawn.
The combined fractions of ethyl acetate (35 mL) were evaporated under nitrogen at 40 #{176}C. The residue was reconstituted in 0.4 mL of sodium phosphate buffer (10 mmol/L, pH 7.4) and a 0.3-mL aliquot was analyzed for 3-O-methyldopamine by radioimmunoassay according to a modified procedure of Faraj et al. other 6-mL portion of scintillation fluid was added to the vial to give a total volume of 12 mL. Each sample was assayed in triplicate. Allsamples were counted to equal ±2% error.
Statistical Analysis
The results obtained in each series were expressed as the arithmetric mean and standard deviation (SD). The sample means were compared by Student's t-test for paired data when appropriate.
Values of p <0.05 were accepted as representing a significant difference. methyldopammne is illustrated in Figures 2 and 3 . We found that concentrations of L-dopa, dopamine, and 3-0-methyldopamine below 12.3, 16.3, and 3 nmol/L, respectively, could not be reliably measured by the above procedure. As previously reported (7), the radioimmunoassay of 3-0-methyldopamine was specific, because several analogs and metabolites of 3-0-methyldopamine showed no appreciable cross reactivity with it.
Results
Analytical Variables
Sensitivity
Analytical recovery.
Analytical recovery was assured by adding known amounts of L-dopa (1.3, 2.6, and 5.2 molTh), dopamine (0.33, 0.66, and 1.65 smol/L), and 3-0-methyldopamine (0.06, 0.3, and 0.6 smol/L) to previously analyzed urine samples, which were then re-analyzed.
The mean analytical recovery of L-dopa, dopamine, and 3-0-methyldopamine for 20 specimens was 65.1 (SD 7.5%), 43.5 (SD 8.3%), and 95.1% (SD 10%), respectively.
Precision. Withinand between-assay variation was assessed for L-dopa, dopamine and 3-0-methyldopamine by assay of 24-h urine samples in the same as well as in a different assay (n = 20), according to the method of Rodbard 
Studies in Humans
In the first part of the study, the concentrations of L-dopa, dopamine, and 3-0-methyldopamine in 24-h urine samples were determined in normal subjects, hospitalized patients without melanoma, and melanoma patients. The results of this study showed that in hospitalized patients with no evidence of melanoma the urinary output of these metabolites did not differ significantly (p >0.05) from that (av ± SD) of normal persons (L-dopa 1.34 ± 0.3, dopamine 147 ± 38, and 3-0-methyldopamine 31.4 ± 13.6 sg/24 h, Table 1 ), but were significantly greater in melanoma patients (L-dopa 5.6 ± 1.2, dopamine 555 ± 121, and 3-O-methyldopamine 178 ± 40.3 g/24 h). Among the melanoma patients, only 30% of those patients with stage I and II, and 80% of those with stage III melanotic melanoma had an abnormal urinary excretion of L-dopa, dopamine, and 3-0-methyldopamine (Table  1) . However, in amelanotic subjects, the average urinary output of these metabolites (1.-dopa 2.25 ± 0.87, dopamine 154 ± 45.21, and 3-0-methyldopamine 36.5 ± 14.8 tg/24 h) did not differ significantly from that in normal or hospitalized nonmelanoma subjects (Table 1) .
In the second part of our study, we evaluated the effect of surgery on the metabolism of L-dopa in melanoma patients. The results (Table 2) demonstrated that four of five cases excreted, pre-operatively, abnormal amounts of dopamine, L-dopa, and 3-0-methyldopamine in their urine. After surgery, there was a substantial decrease in the urinary excretion of these metabolites as measured 72 h postoperatively in four of the five patients.
Discussion
Here we have described a specific and sensitive assay that allows simultaneous measurement of 1.-dopa and its metabolites, dopamine and 3-0-methyldopammne, in urine. Aromatic-L-amino-acid decarboxylase (EC 4.1.1.28) and catechol methyltransferase, important enzymes in the biosynthesis and metabolism of catecholamines in the central and peripheral nervous system, were isolated from rat kidney and liver and partly purified by repeated precipitation with ammonium sulfate. The determination of catechol methyltransf'erase activity was based on the principle that the enzyme catalyzes the transfer of methyl groups to substrates containing the catechol moiety in the presenceofS-adenosylmethionine as the methyl donor and magnesium ions as the activator. In this case, L-dopa and dopamine were used as the substrates for the
The end product of the enzymatic reaction, 3-0-methyldopamine, was measured by radioimmunoassay (7). In spite of the broad substrate specificity of catechol methyltransferase, all known substrates are characterized by a catechol configuration, regardless of other substituents in the aromatic ring. The unique feature of the enzyme-radioimmunoassay of L-dopa and dopammne is its ability to identify the 0-methylated dopamine product directly in the reaction mixture by our specific radioimmunoassay without prior chromatographic separation of the 3-0- Figure  1) . Although the details of melanin synthesis are yet to be worked out, the rate-limiting steps in melanogenesis seem to occur at the level of oxidation of tyrosine to L-dopa and L-dopa to dopaquinone.
The enzyme tyrosinase catalyzes both conversions. In summary, the approach presented here for determination of 1.-dopa and its metabolites, dopamine and 3-0-methyldopamine, is rapid and reliable. The assay may provide a more specific and comprehensive biochemical profile for detection of melanotic melanoma. It may also be helpful in monitoring the course of this disease and in assessing the efficacy of treatment.
